175 related articles for article (PubMed ID: 35201622)
41. Scoping the family history: assessment of Lynch syndrome (hereditary nonpolyposis colorectal cancer) in primary care settings--a primer for nurse practitioners.
Maradiegue A; Jasperson K; Edwards QT; Lowstuter K; Weitzel J
J Am Acad Nurse Pract; 2008 Feb; 20(2):76-84. PubMed ID: 18271762
[TBL] [Abstract][Full Text] [Related]
42. Screening, diagnosis, and management of prostate cancer: improving primary care outcomes.
Goolsby MJ
Nurse Pract; 1998 Mar; 23(3):11-4,16,21-3 passim; quiz 42-3. PubMed ID: 9560828
[TBL] [Abstract][Full Text] [Related]
43. Updates in hereditary breast cancer genetic testing and practical high risk breast management in gene carriers.
Pederson HJ; Noss R
Semin Oncol; 2020 Aug; 47(4):182-186. PubMed ID: 32513422
[TBL] [Abstract][Full Text] [Related]
44. Primary Care Implications of the Expanded National Guidelines for Germline Testing of Patients Previously Diagnosed with Colorectal Cancer.
Sorscher S
J Am Board Fam Med; 2023 Apr; 36(2):360-365. PubMed ID: 36801845
[TBL] [Abstract][Full Text] [Related]
45. Prostate Cancer Screening in a New Era of Genetics.
Cheng HH; Pritchard CC; Montgomery B; Lin DW; Nelson PS
Clin Genitourin Cancer; 2017 Dec; 15(6):625-628. PubMed ID: 28697982
[TBL] [Abstract][Full Text] [Related]
46. Evidence-based medical perspectives: the evolving role of PSA for early detection, monitoring of treatment response, and as a surrogate end point of efficacy for interventions in men with different clinical risk states for the prevention and progression of prostate cancer.
Lieberman R
Am J Ther; 2004; 11(6):501-6. PubMed ID: 15543092
[TBL] [Abstract][Full Text] [Related]
47. Risk perception, screening practice and interest in genetic testing among unaffected men in families with hereditary prostate cancer.
Bratt O; Damber JE; Emanuelsson M; Kristoffersson U; Lundgren R; Olsson H; Grönberg H
Eur J Cancer; 2000 Jan; 36(2):235-41. PubMed ID: 10741283
[TBL] [Abstract][Full Text] [Related]
48. Familial prostate cancer.
Giri VN; Beebe-Dimmer JL
Semin Oncol; 2016 Oct; 43(5):560-565. PubMed ID: 27899188
[TBL] [Abstract][Full Text] [Related]
49. Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer.
Isaacsson Velho P; Silberstein JL; Markowski MC; Luo J; Lotan TL; Isaacs WB; Antonarakis ES
Prostate; 2018 Apr; 78(5):401-407. PubMed ID: 29368341
[TBL] [Abstract][Full Text] [Related]
50. Risk assessment and genetic counseling for hereditary breast and ovarian cancer syndromes-Practice resource of the National Society of Genetic Counselors.
Berliner JL; Cummings SA; Boldt Burnett B; Ricker CN
J Genet Couns; 2021 Apr; 30(2):342-360. PubMed ID: 33410258
[TBL] [Abstract][Full Text] [Related]
51. Genetic counseling and previvorship in patients with urologic malignancies.
Jacobs MF; Milliron KJ
Curr Opin Urol; 2019 Jul; 29(4):371-377. PubMed ID: 31033576
[TBL] [Abstract][Full Text] [Related]
52. Ethnic disparities among men with prostate cancer undergoing germline testing.
Kwon DH; Borno HT; Cheng HH; Zhou AY; Small EJ
Urol Oncol; 2020 Mar; 38(3):80.e1-80.e7. PubMed ID: 31630993
[TBL] [Abstract][Full Text] [Related]
53. "It's all very well reading the letters in the genome, but it's a long way to being able to write": Men's interpretations of undergoing genetic profiling to determine future risk of prostate cancer.
Bancroft EK; Castro E; Ardern-Jones A; Moynihan C; Page E; Taylor N; Eeles RA; Rowley E; Cox K
Fam Cancer; 2014 Dec; 13(4):625-35. PubMed ID: 24980079
[TBL] [Abstract][Full Text] [Related]
54. Germline mutation prevalence in individuals with pancreatic cancer and a history of previous malignancy.
Dudley B; Karloski E; Monzon FA; Singhi AD; Lincoln SE; Bahary N; Brand RE
Cancer; 2018 Apr; 124(8):1691-1700. PubMed ID: 29360161
[TBL] [Abstract][Full Text] [Related]
55. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
56. Initial Findings from a High Genetic Risk Prostate Cancer Clinic.
Sessine MS; Das S; Park B; Salami SS; Kaffenberger SD; Kasputis A; Solorzano M; Luke M; Vince RA; Kaye DR; Borza T; Stoffel EM; Cobain E; Merajver SD; Jacobs MF; Milliron KJ; Caba L; van Neste L; Mondul AM; Morgan TM
Urology; 2021 Oct; 156():96-103. PubMed ID: 34280438
[TBL] [Abstract][Full Text] [Related]
57. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.
Mandelker D; Zhang L; Kemel Y; Stadler ZK; Joseph V; Zehir A; Pradhan N; Arnold A; Walsh MF; Li Y; Balakrishnan AR; Syed A; Prasad M; Nafa K; Carlo MI; Cadoo KA; Sheehan M; Fleischut MH; Salo-Mullen E; Trottier M; Lipkin SM; Lincoln A; Mukherjee S; Ravichandran V; Cambria R; Galle J; Abida W; Arcila ME; Benayed R; Shah R; Yu K; Bajorin DF; Coleman JA; Leach SD; Lowery MA; Garcia-Aguilar J; Kantoff PW; Sawyers CL; Dickler MN; Saltz L; Motzer RJ; O'Reilly EM; Scher HI; Baselga J; Klimstra DS; Solit DB; Hyman DM; Berger MF; Ladanyi M; Robson ME; Offit K
JAMA; 2017 Sep; 318(9):825-835. PubMed ID: 28873162
[TBL] [Abstract][Full Text] [Related]
58. Genetic Testing and Its Clinical Application in Prostate Cancer Management: Consensus Statements from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology.
Chiu PKF; Lee EKC; Chan MTY; Chan WHC; Cheung MH; Lam MHC; Ma ESK; Poon DMC
Front Oncol; 2022; 12():962958. PubMed ID: 35924163
[TBL] [Abstract][Full Text] [Related]
59. Awareness of genetic counseling and genetic testing for hereditary gynecologic cancers among Korean healthcare providers: A survey.
Kim M; Cheol Lim M; Ji Nam E; Huang D; Kim S; Jong Yoo H; Lee YY; Chang YJ;
J Genet Couns; 2022 Apr; 31(2):546-553. PubMed ID: 34674340
[TBL] [Abstract][Full Text] [Related]
60. Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians.
Merseburger AS; Waldron N; Ribal MJ; Heidenreich A; Perner S; Fizazi K; Sternberg CN; Mateo J; Wirth MP; Castro E; Olmos D; Petrylak DP; Chowdhury S
Eur Urol; 2021 Apr; 79(4):519-529. PubMed ID: 33494937
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
